Skape Bio Launches Nature-Published Platform for AI-Designed GPCR Biotherapeutics
Nature study describes a de novo protein design and high-throughput living-cell screening platform for creating miniproteins that modulate G protein-coupled receptors (GPCRs), a major class of drug targets.
The study produced functional lead molecules against 11 GPCR targets, including receptors involved in cancer, diabetes, obesity, migraine, itch, and pain.
The work lays the foundation for Skape’s platform to develop therapeutics against hard-to-target GPCRs, with Nobel laureate David Baker and colleagues at the University of Washington’s Institute for Protein Design.
Skape Bio and researchers at the University of Washington’s Institute for Protein Design (IPD) today announced a peer-reviewed study published in the leading international journal Nature demonstrating a new way to design protein-based medicines for G protein-coupled receptors, or GPCRs, one of the most important classes of drug targets in medicine.
